



HPV

HUMAN PAPILLOMAVIRUS VACCINE INTRODUCTION



Globally, cervical cancer kills more than 250,000 women every year and 85 percent of these deaths occur in low- and middle income countries. Two types of HPV cause 70 percent of cervical cancers and precancerous cervical lesions. When provided to young girls between 9 and 14 years old, the HPV vaccine is the most cost-effective public health measure to prevent HPV and therefore cervical cancer.

Since 2013 with funding from Gavi, the Vaccine Alliance, JSI has provided technical assistance to 7 countries introducing the human papilloma virus (HPV) vaccine nationwide. Vaccination efforts focused on reaching pre-adolescent/adolescent girls before they are at risk of exposure in Kenya, Cameroon, Zimbabwe, Tanzania, Madagascar, Malawi, and Mozambique. JSI also supported the HPV vaccination demonstration projects in Niger, Madagascar, and Zimbabwe.

JSI provides targeted technical assistance to HPV vaccine introduction efforts based on the needs and national roll-out plans in each country, in close collaboration with the Ministry of Health's Expanded Program on Immunization (EPI), Ministry of Education (and other government programs), Gavi, WHO, UNICEF and other partners.




JSI's country-based technical staff are supporting activities such as preparation for the HPV vaccine grant application to Gavi, integration of the HPV vaccine into the country planning, partner coordination and engagement, and communication and social mobilization. JSI also provides technical assistance with training and capacity building of health care workers, analysis of

HPV vaccine delivery and cold chain/logistics readiness and tracking, and supportive supervision and monitoring during and post-introduction.



JSI has over 30 years of experience in immunization and has supported 75 new vaccine introductions in 24 countries.



OUR IMPACT

HPV Vaccine National Introduction Technical Assistance in Cameroon, Kenya, Malawi, Tanzania, and Zimbabwe

Through funding from Gavi, JSI supports the preparation and national introduction of the HPV vaccine in Cameroon, Kenya, Malawi, Tanzania, and Zimbabwe. JSI, in close collaboration with the Ministry of Health, EPI, Gavi, WHO, UNICEF and other partners, provides targeted technical assistance to HPV vaccine introduction efforts based on the needs and introduction status of each country. Technical assistance in each country includes activities such as integration of the HPV vaccine into the country's routine immunization system, partner coordination and engagement with ongoing and new partners that have not



previously supported the EPI, and communication and social mobilization including innovative approaches to reaching a new target population (9-14 year old girls). JSI staff train and build the capacity of health care workers, teachers and community leaders, analyze HPV vaccine delivery and cold chain/logistics readiness, and provide supportive supervision and monitoring during and post-introduction.

HPV Vaccine Pilot Introduction Technical Assistance in Madagascar

Beginning In November 2013, with assistance from JSI, Gavi and partners, the Government of Madagascar (GoM) began vaccinating adolescent girls with the life-saving HPV vaccine in an effort to combat the detrimental effects of HPV infection on a population of over 7 million Malagasy women at risk. The GoM, with technical assistance from JSI, conducted a series of pilot introductions of the HPV vaccine to identify the most effective strategy for reaching the target population given the financial, human resource, and health system constraints.

For more information or resources on JSI's work in HPV and vaccine introduction, please visit our website at <https://www.jsi.com/hpv> or email Lora Shimp at Lshimp@jsi.com.

HPV Vaccine Pilot Introduction Technical Assistance in Niger

JSI, with funding from Gavi and in collaboration with partners, supported the Government of Niger to complete phase I of an HPV vaccine pilot introduction in three districts—two urban and one rural—in December 2014 and conduct a post-introduction evaluation, coverage survey and cost study. Building on the lessons learned from the initial pilot, JSI also supported the completion of Phase II of the pilot introduction in July 2018.



HPV Vaccine Introduction Grant Technical Assistance in Mozambique

As countries prepare for the introduction of the HPV vaccine, there is a need for partner and stakeholder coordination to prepare an application to Gavi for a Vaccine Introduction Grant. In Mozambique, JSI facilitated a stakeholder workshop to develop and then submit the HPV vaccine grant application to Gavi building on best practices from other countries that have already introduced and lessons learned from the prior demonstration.